Results 251 to 260 of about 89,575 (313)

Helicopter EMS for scene response to head-injured patients: systematic review & meta-analysis. [PDF]

BMC Emerg Med
Fritz CL, Rosen CL, Thomas CE, Kim AJ, Price J, Hibberd O, Galvagno S, Schoenfeld DW, Thomas SH.   +8 more
europepmc   +1 more source

Fiscal Effects of Reforming the UK State Pension System [PDF]

, 2007
Blundell, R, Emmerson, C
core  

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Maintaining quality of scientific peer-review and publishing in <i>Physics and Imaging in Radiation Oncology</i>. [PDF]

Phys Imaging Radiat Oncol
Knäusl B, Solberg TD, Thorwarth D, Muren LP.   +3 more
europepmc   +1 more source

New Rochelle, City of and New Rochelle School Crossing Guards Unit, CSEA, Local 1000 AFSCME, AFL-CIO, Westchester Local 860 (2008) [PDF]

, 2008

core   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

SATURN MRI: study protocol for the statin use in intracerebral hemorrhage patients MRI ancillary study. [PDF]

Trials
Marchina S, Foster LD, Yeatts SD, Khatri P, Bernstein K, Perlmutter A, Heistand EC, Smith EE, Sharma M, Broderick JP, Lioutas VA, Marti-Fabregas J, Selim M, Shoamanesh A.   +13 more
europepmc   +1 more source

ACCRUAL ACCOUNTING AND THE PUBLIC SECTOR [PDF]

Marc Robinson
core  

Does an optimistic tone in annual reports predict better financial and non‐financial performance?

European Management Review, EarlyView.
Abstract In the current paper, we investigate whether management adopts an optimistic disclosure tone to impress the corporate audience or to provide incremental information (II) by anticipating positive corporate performance. Specifically, we test whether an optimistic tone in annual reports (ARs) is a positive predictor of better financial and non ...
Francesco Gangi, Daniele Angelo Previati, Lucia Michela Daniele, Giuseppe Galloppo   +3 more
wiley   +1 more source

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. [PDF]

Target Oncol
Michaeli DT, Michaeli T, Albers S, Michaeli JC.   +3 more
europepmc   +1 more source